Aptinyx Inc. (NASDAQ:APTX) Short Interest Update

Aptinyx Inc. (NASDAQ:APTXGet Rating) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 326,500 shares, a drop of 10.6% from the October 15th total of 365,400 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 418,600 shares, the days-to-cover ratio is currently 0.8 days.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. HC Wainwright lowered their price target on shares of Aptinyx from $2.00 to $1.00 and set a “buy” rating for the company in a report on Friday, August 26th. Cowen lowered shares of Aptinyx from an “outperform” rating to a “market perform” rating in a report on Monday, August 15th. BMO Capital Markets lowered their price objective on shares of Aptinyx from $6.00 to $2.00 and set an “outperform” rating for the company in a research note on Monday, August 15th. Piper Sandler lowered shares of Aptinyx from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $6.00 to $2.00 in a research note on Friday, August 12th. Finally, Truist Financial lowered shares of Aptinyx from a “buy” rating to a “hold” rating in a research note on Monday, August 15th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Aptinyx currently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On Aptinyx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC raised its stake in Aptinyx by 213.3% in the 3rd quarter. Jane Street Group LLC now owns 105,771 shares of the company’s stock valued at $39,000 after acquiring an additional 72,006 shares during the period. LGL Partners LLC bought a new stake in shares of Aptinyx during the first quarter valued at about $44,000. Assenagon Asset Management S.A. increased its position in shares of Aptinyx by 70.9% during the second quarter. Assenagon Asset Management S.A. now owns 116,814 shares of the company’s stock valued at $65,000 after buying an additional 48,476 shares during the period. Cetera Advisor Networks LLC bought a new stake in shares of Aptinyx during the first quarter valued at about $92,000. Finally, Renaissance Technologies LLC increased its position in shares of Aptinyx by 116.4% during the second quarter. Renaissance Technologies LLC now owns 568,914 shares of the company’s stock valued at $317,000 after buying an additional 305,988 shares during the period. 50.62% of the stock is currently owned by institutional investors.

Aptinyx Price Performance

Shares of NASDAQ:APTX opened at $0.33 on Friday. The company’s 50-day moving average is $0.35 and its 200 day moving average is $0.47. The company has a debt-to-equity ratio of 0.51, a quick ratio of 27.45 and a current ratio of 27.45. The company has a market capitalization of $22.35 million, a P/E ratio of -0.31 and a beta of 1.14. Aptinyx has a fifty-two week low of $0.20 and a fifty-two week high of $3.76.

About Aptinyx

(Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Read More

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.